8-K: Syndax Reports Strong 2025 Revenue, Advances Pipeline

Syndax Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant growth in Revuforj and Niktimvo sales, and provided positive updates on its clinical pipeline.

Summary

• Total revenue for the full year 2025 reached $172.4 million, a substantial increase from $23.7 million in 2024.
• Revuforj net revenue for the full year 2025 was $124.8 million, with $44.2 million in Q4 2025, representing a 38% quarter-over-quarter increase.
• Niktimvo net revenue for the full year 2025 was $151.6 million (reported by Incyte), contributing $42.4 million in collaboration revenue to Syndax, with $19.4 million in Q4 2025, a 22% quarter-over-quarter increase.
• The company reported a net loss attributable to common stockholders of $285.4 million, or $3.29 per share, for the full year 2025, an improvement from a $318.8 million net loss in 2024.
• Cash, cash equivalents, and short-term investments stood at $394.1 million as of December 31, 2025.
• Enrollment was completed in the Phase 2 IPF trial of axatilimab, with topline data expected in Q4 2026.
• Syndax initiated REVEAL-ND, a Phase 3 trial for revumenib in newly diagnosed NPM1m AML patients, in November 2025.
• The company expects total research and development plus selling, general and administrative expenses for 2026 to be approximately $400 million, excluding $50 million in estimated non-cash stock compensation expense.
• Syndax anticipates its operating expense base to remain stable over the next couple of years and expects to reach profitability with current cash and anticipated revenues.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, reflecting strong commercial execution for two recently launched products and significant progress in expanding their clinical pipelines. The substantial revenue growth and clear path to profitability are strong indicators of future value, despite ongoing net losses.

Positives

• Total revenue for FY2025 significantly increased to $172.4 million from $23.7 million in FY2024, demonstrating strong commercial execution.
• Revuforj net revenue grew 38% quarter-over-quarter to $44.2 million in Q4 2025, totaling $124.8 million for FY2025, driven by accelerated demand post-FDA approval for R/R NPM1m AML.
• Niktimvo net revenue increased 22% quarter-over-quarter to $56.0 million in Q4 2025, contributing $42.4 million in collaboration revenue to Syndax for FY2025, surpassing launch benchmarks in 3L+ cGVHD.
• Net loss for FY2025 decreased to $285.4 million from $318.8 million in FY2024, indicating progress towards profitability.
• Completed enrollment in the MAXPIRe Phase 2 IPF trial for axatilimab, with topline data anticipated in Q4 2026, potentially expanding Niktimvo's market opportunity.
• Initiated REVEAL-ND, a pivotal Phase 3 trial for revumenib in newly diagnosed NPM1m AML, positioning the company to be first to frontline AML with a menin inhibitor.
• Revuforj received the 'Best New Drug' award at the Scrip Awards in December 2025, recognizing its therapeutic advance.
• Presented compelling real-world evidence for revumenib, showing an overall response rate of 77% and MRD negativity rate of 75% in acute leukemia patients.

Negatives

• The company continues to operate at a significant net loss, reporting $285.4 million for the full year 2025.
• Cash, cash equivalents, and short-term investments decreased to $394.1 million as of December 31, 2025, from $692.4 million in 2024, reflecting a high burn rate.
• Research and development expenses increased to $258.8 million in FY2025 from $241.6 million in FY2024, driven by increased clinical, medical, and employee-related expenses.
• Selling, general and administrative expenses increased to $179.7 million in FY2025 from $120.9 million in FY2024, primarily due to increased employee-related expenses and sales and marketing for product launches.

Risks

• Unexpected safety or efficacy data observed during preclinical or clinical trials could impact product development and approval.
• Clinical trial site activation or enrollment rates may be lower than expected, delaying development timelines.
• Changes to Revuforj's or Niktimvo's commercial availability could affect revenue generation.
• Changes in expected or existing competition could impact market share and pricing power.
• Changes in the regulatory environment may create hurdles for product approvals or commercialization.
• Failure of Syndax's collaborators to support or advance collaborations or product candidates could hinder pipeline progress.
• Unexpected litigation or other disputes could result in significant financial and reputational costs.
• Macroeconomic conditions, such as the Russia-Ukraine war and inflation, could delay or disrupt clinical trials, manufacturing, supply chain, or impair employee productivity.

Future Outlook

Syndax expects its total research and development plus selling, general and administrative expenses for the full year 2026 to be approximately $400 million, excluding $50 million in estimated non-cash stock compensation expense. The company anticipates its operating expense base will remain stable over the next couple of years and projects that its current cash, combined with anticipated product revenue, collaboration revenue, and interest income, will enable it to reach profitability. Key upcoming milestones include presenting additional revumenib data throughout 2026, initiating the RAVEN trial in 2H 2026, and reporting topline Phase 2 axatilimab data in IPF in Q4 2026.

Management Comments

• Michael A. Metzger, CEO, stated, "We solidified our leadership position and proved the strength of Syndax's R&D and commercial capabilities in 2025, achieving our third FDA approval and successfully launching two firstand best-in-class medicines."
• Mr. Metzger highlighted, "We reached thousands of patients with Revuforj and Niktimvo and generated over $275 million in 2025 sales, rapidly advancing the company towards profitability."
• Mr. Metzger added, "With strong momentum and multiple growth drivers for both products, including increasing uptake of Revuforj in R/R NPM1m AML and the post-transplant setting, Syndax is well positioned for continued growth in 2026 and beyond."
• Mr. Metzger also noted, "We've also made excellent progress advancing our development programs designed to further unlock multi-billion-dollar opportunities for both our medicines."
• He further commented, "We are positioned to be first to frontline AML with a menin inhibitor, and to expand our impact on chronic GVHD and other fibrotic diseases through CSF-1R inhibition."
• Mr. Metzger concluded, "Earlier this year, we completed enrollment in our Phase 2 IPF trial and remain on track for topline data later this year which could further unlock Niktimvo's potential as a novel antifibrotic."

Industry Context

StockSavvy.ai notes that Syndax Pharmaceuticals is solidifying its position in the highly competitive oncology and rare disease markets with two recently approved and commercially successful products, Revuforj and Niktimvo. Revuforj's strong first-year performance, surpassing AML launch benchmarks, positions Syndax as a leader in menin inhibition, a novel targeted therapy area. The company's strategic focus on expanding Revuforj into frontline AML and Niktimvo into first-line chronic GVHD and idiopathic pulmonary fibrosis (IPF) aligns with broader industry trends towards earlier intervention and addressing unmet needs in fibrotic diseases. The reported total addressable market (TAM) of over $5 billion for Revuforj across acute leukemia and $5 billion for Niktimvo across cGVHD and IPF indicates significant growth potential, placing Syndax favorably against competitors in these therapeutic areas.

Comparison to Industry Standards

• Revuforj's first-year results, with $124.8 million in net revenue and approximately 3,350 cumulative prescriptions, are stated to surpass AML launch benchmarks, indicating strong market penetration and adoption compared to other targeted AML therapies like FLT3 inhibitors or IDH inhibitors in their initial launch phases.
• Niktimvo's performance, achieving approximately 20% share of the 3L+ cGVHD market in its first 11 months, is noted to surpass launch benchmarks for third-line plus chronic GVHD treatments, suggesting a rapid uptake relative to other therapies in this indication.
• The company's ambition to be 'first to frontline AML with a menin inhibitor' positions it ahead of other developers in this specific mechanism of action for a significant market segment.
• The reported overall response rate (ORR) of 77% and measurable residual disease (MRD) negativity rate of 75% for revumenib in real-world evidence for R/R NPM1m, KMT2Ar, and NUP98r acute leukemia patients are compelling and compare favorably to historical response rates for salvage therapies in these difficult-to-treat populations.
• The 100% MRD negativity rate among responders in the SAVE trial (revumenib with venetoclax and decitabine/cedazuridine) and BEAT AML trial (revumenib with venetoclax and azacitidine) for newly diagnosed AML patients is a strong indicator of deep responses, potentially superior to standard chemotherapy alone or other combination regimens.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, pipeline expansion, and a stated path to profitability.
• Patients: Positive impact through the successful launch and continued development of innovative therapies for acute leukemia, chronic GVHD, and potentially IPF.
• Employees: Continued growth and pipeline advancement suggest stability and potential for expansion within the company.
• Partners (Incyte, HOVON network, MD Anderson Cancer Center, City of Hope Medical Center, Break Through Cancer, Australasian Leukaemia and Lymphoma Group): Ongoing successful collaborations and clinical trial progress reinforce the value of these partnerships.

Next Steps

• Advance global enrollment in pivotal first-line (1L) trials of revumenib.
• Publish and present industry-leading clinical data, including 1L, maintenance, and real-world evidence for revumenib throughout 2026.
• Report topline Phase 2 axatilimab data in Idiopathic Pulmonary Fibrosis (IPF) in Q4 2026.
• Initiate the RAVEN 1L trial of revumenib in fit KMT2Ar patients in the second half of 2026.
• Initiate a program to generate proof-of-principle clinical data with revumenib in myelofibrosis.
• Host a conference call and live audio webcast on February 26, 2026, at 4:30 p.m. ET to discuss results and business updates.

Key Dates

Recommendation

The filing demonstrates exceptional commercial execution with both Revuforj and Niktimvo significantly exceeding prior year revenues and launch benchmarks. The company's clear path to profitability, stable expense outlook, and robust clinical pipeline with multiple near-term catalysts (e.g., IPF data, new trial initiations) suggest strong future growth potential. While still operating at a net loss, the substantial reduction in loss and strong revenue trajectory indicate a positive inflection point, making it an attractive investment for long-term growth.

Keywords

Syndax Pharmaceuticals, SNDX, Financial Results, Q4 2025, FY 2025, Revuforj, revumenib, Niktimvo, axatilimab-csfr, AML, Acute Myeloid Leukemia, NPM1m, KMT2Ar, Menin Inhibitor, Chronic GVHD, Graft-versus-host disease, CSF-1R inhibitor, Idiopathic Pulmonary Fibrosis, IPF, Clinical Trials, Biopharmaceutical, Oncology, Hematology, FDA Approval, Commercial Stage